Optimizing timing and dose of exogenous melatonin administration in neuropsychiatric pediatric populations: a...

Area of Science:

• Pediatric Neurology
• Sleep Medicine
• Pharmacology

Background:

• Melatonin is recognized for its sleep-promoting effects in children with neuropsychiatric disorders.
• Current clinical practice lacks specific guidelines for optimal melatonin dosing and administration schedules in this population.

Purpose of the Study:

• To systematically review and meta-analyze existing research to determine the most effective melatonin dose, timing, and duration for pediatric sleep disturbances.
• To identify treatment parameters associated with maximal efficacy in children with neurological and psychiatric conditions.

Main Methods:

• A systematic literature search adhering to PRISMA guidelines was conducted up to April 30, 2024, including 21 studies.
• Meta-regression models and dose-response curves were used to analyze sleep-related variables (e.g., sleep onset latency, sleep efficiency, total sleep time) comparing melatonin to placebo.
• Key treatment parameters including dose, time of administration, and duration were evaluated for their impact on efficacy.

Main Results:

• Melatonin significantly decreased sleep onset latency and increased sleep efficiency and total sleep time.
• Earlier administration (closer to bedtime) correlated with reduced sleep onset latency.
• Increased sleep efficiency and total sleep time were associated with longer treatment durations. Maximal efficacy was observed with doses between 2-4 mg/day.

Conclusions:

• A melatonin dosage of 2-4 mg administered 3 hours before bedtime, combined with extended treatment duration, appears to maximize sleep-promoting effects in pediatric patients with neuropsychiatric conditions.
• These findings provide evidence-based recommendations that could inform clinical practice, pending validation through large-scale clinical trials.